ArticleFrontiers in bioengineering and biotechnology2026
Serum-free production of anti-huCD20(hγ1)-IL2no-alpha immunocytokine: a promising therapeutic for B-NHL.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mammalian cell cultures are widely used for producing complex biopharmaceuticals that require human-like post-translational modifications, such as antibody-based therapeutics. Traditionally, serum-supplemented media support high cell viability and productivity; however, regulatory and scientific requirements demand serum-free conditions for clinical-grade manufacture. Recently, a novel fusion protein, the anti-huCD20(hγ1)-IL2no-alpha immunocytokine (IC), was presented as a promising therapeutic alternative, mostly for relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients, considering currently approved therapies. Methods: Three Chinese hamster ovary clones (K1 strain) producing the anti-huCD20(hγ1)-IL2no-alpha IC were generated and adapted to serum-free suspension culture. We performed a kinetic characterization of one clone in two culture media with different nutritional compositions, evaluating cell growth, productivity, cell cycle progression and mTOR signaling. The IC was purified by Protein A, then evaluated for identity, aggregation profile, CD20 recognition, CTLL-2 cytokine activity, ex vivo B-cell depletion in PBMC from r/r B-NHL patients and antitumor efficacy in immunocompetent C57BL/6 mice bearing EL4-hCD20- cells. Results: The results demonstrated noticeable differences in cell growth and productivity in both batch and pseudo-perfusion performance, likely due to an influence on cell-cycle progression and mTOR signaling. The purified IC maintained its structural integrity while exhibiting an improved aggregation profile compared to serum-containing cultures. Furthermore, key biological activities, including B-cell depletion and antitumoral effects, remained intact. Discussion: This research highlights the successful serum-free production of a functional anti-huCD20(hγ1)-IL2no-alpha IC, reinforcing its potential for biopharmaceutical development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.